Congratulations to our client KalVista Pharmaceuticals, Inc. for appointing Bethany Sensenig, MBA, CMA as Board Director & Audit Committee Member.
KalVista Pharmaceuticals is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Their commitment to rigorous science is driven by their determination to better address treatment needs for patients, beginning with their first product for hereditary angioedema (HAE), a rare genetic disease with unpredictable attacks of tissue swelling that can be life threatening.
C1 Team: Christos Richards, Jed Donnelly, Evan Fishel, & Justine Navarrette